

CURRICULUM VITAE

Prof. Dr. med. Beat Müller



A. Personalien

Geburt 15. März 1965 in Bern
Heimatort Basel-Stadt und Bubendorf (BL), Schweizer Bürger
Zivilstand verheiratet mit Beatrice Ackermann Müller (seit 1991)
3 Kinder: Laura *1994, Jonas *1996, Lars *1998
Adresse Bruderholzallee 196, CH-4059 Basel
T / M: +4179 480 7989; E: Beat.Mueller@HormoKine.com

B. Erfahrungen im verwaltungsrätlichen, geschäftsführenden & unternehmerischen Bereich

Jun 2010 – Jun 2023 **Verwaltungsrat** (Governing Board) **Argomed AG**, Lenzburg (AG)
Aug 2012 – Jun 2018 **Mitglied der Geschäftsleitung** (Executive Board) Kantonsspital Aarau AG
Jan 2016 – **Verwaltungsrat** (Governing Board) **Psychiatrie Basel-Land (PBL)**, Liestal (BL)
Jan 2017 Gründung **Criweba AG** – Entwicklung von Evidenz-basierten medizinischen Algorithmen
Nov 2019 – Nov 2022 **Präsident Schweizerische Gesellschaft Endokrinologie & Diabetologie** (SGED/SSGD)
Jul 2021 – Apr 2023 **Mitglied der Geschäftsleitung** (Executive Board) Kantonsspital Aarau AG
Apr 2023 Gründung **HormoKine GmbH** – Nachhaltigere Medizin & Spitalmanagement

C. Aus- & Weiterbildung, Medizinische und Akademische Erfahrung

1972 – 1984 Primar- und Sekundarschule, Gymnasium Bern, Matura Typus E (Wirtschaft)
1984 – 1990 Medizinstudium, Universität Bern & Südafrika (Elim Hospital, Gazankulu)
12. Dez 1990 **Schweizer Staatsexamen & Dissertation:** "In Presseorganen angepriesene Schlankheitskuren" (Proff. M.P. König, U. Bürgi, Bern)
8. Jan 1991 **US Medical Exam** (FMGEMS I&II, TOEFL), ECFMG, Philadelphia, PA, USA
Feb – Okt 1991 Militärdienst, Leutnant abverdienen als Schularzt, **Oberleutnant** (a.D. 2000)
1991 – 1996 Weiterbildung zum Facharzt Innere Medizin und Endokrinologie/Diabetologie
- Abt. für Endokrinologie, Dept. Innere Medizin, Universitätsspital Basel (Prof. J.J. Staub)
- Medizinische Universitätsklinik, Kantonsspital Liestal, BL (Prof. A. Rosenmund)
- Dept. Innere Medizin, Universitätsspital Basel (Prof. J. A. Schifferli)
Aug 1996 **Facharzt Innere Medizin** (FMH)
Aug 1996 – Mar 1997 Oberarzt, Dept. Innere Medizin, Universitätsspital Basel, Prof. J. A. Schifferli
Jul 1997 – Sep 1999 Postdoctoral Research Fellowship, Lab of Molecular Endocrinology (Prof. J.F. Habener), **Harvard University**, Massachusetts General Hospital, Boston, USA
Okt 1999 – Sep 2000 Weiterbildung, Abt. Endokrinologie, Diabetologie and klinische Ernährung Universitätsspital Basel (USB), Proff. U. Keller & J.J. Staub
Okt 2000 – Aug 2001 Oberarzt, 80% Dept. Innere Medizin (Prof. A. P. Perruchoud), 20% Klinik für Endokrinologie, Diabetologie und klinische Ernährung (Proff. U. Keller, J.J. Staub), USB
Sep 2001 **Facharzt Endokrinologie und Diabetologie** (FMH)
8. Nov 2002 Venia docendi für Innere Medizin (Postdoctoral Thesis, **Habilitation**)
8. Dez 2004 **Titular Professur** für Innere Medizin & Endokrinologie
Sep 2001 – Mar 2008 Stv. Chefarzt, Klinik für Endokrinologie, Diabetologie & klinische Ernährung, Bereich Medizin, Universitätsspital Basel
Apr 2008 – Jul 2023 **Bereichsleiter Medizin & Direktor / Leiter Medizinische Klinik**, Kantonsspital Aarau AG
Apr 2008 – Dez 2018 **Chefarzt Abt. für Allgemeine Innere und Notfallmedizin**, Kantonsspital Aarau AG
Jan 2009 – Jul 2023 **Chefarzt Abt. Endokrinologie, Diabetologie, Metabolismus**, Kantonsspital Aarau AG
Jul. 2011 – Dez 2014 **Leiter SIC** (Stroke Unit, Intermediate Care, Coronary Care Unit)
Mai 2010 – Jul 2023 **Leiter Universitätsklinik der Medizinischen Fakultät Basel, Kantonsspital Aarau AG**
Mai 2010 – Jul 2024 **Ordinarius für Medizin & Endokrinologie** („Argovia Professor für Outcome Forschung“)

III. BIBLIOGRAPHIE - PUBLIKATIONSLISTE

Stand 05. September 2023

Orchid-ID: 0000-0002-1986-2511

Researcher ID: <http://www.researcherid.com/rid/G-2662-2012>

Research Gate: >97.5 Percentile

H-Index: 82 (78 excl. self-references)

Impact Factors (IF): > 3500

A. Originalarbeiten (Auswahl: preisgekrönt, sog. *Landmarkstudies*, Studien zu Prozess- & Spitalmanagement)

3. Müller B., Zulewski H., Huber P., Ratcliffe J.G., Staub J.J. Impaired Action of Thyroid Hormone Associated with Smoking in Women with Hypothyroidism. **New Engl J Med** 1995; 333: 964-9 IF 79.3
Editorial: Utiger R.D. Cigarette Smoking and the Thyroid. **New Engl J Med** 1995; 333: 1001-2
Award: Prize of the Swiss Society of Internal Medicine (SGIM) 1995
6. Müller B., Becker K.L., Schächinger H., Rickenbacher P.R., Huber P.R., Zimmerli W., Ritz R. Calcitonin Precursors are Reliable Markers of Sepsis on a Medical Intensive Care Unit. **Crit Care Med** 2000; 28: 977-83 IF 6.3
Editorials: - Vincent J.L. Procalcitonin: THE marker of sepsis? **Crit Care Med** 2000; 28(4): 1226-7
- Boucher BA. Procalcitonin: Clinical tool or laboratory curiosity? **Crit Care Med** 2000; 28(4): 1224-5
Award: 1st Annual Prize for Medical Intensive Care (Krokus Foundation) 2001
9. Müller B., White J.C., Nylen E., Snider R.S. Becker K.L., Habener J.F. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. **J Clin Endocrinol Metab** 2001; 86 396-404 IF 6.3
10. Zulewski H., Abraham E.J., Gerlach M.J., Daniel P.B., Moritz W., Müller B., Vallejo M., Thomas M.K., Habener J.F. Multipotential Nestin-Positive Stem Cells Isolated from Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes. **Diabetes** 2001; 50: 521-33 IF 8.3
12. Meier C., Staub J.J., Roth C.B., Guglielmetti M., Kunz M., Miserez A.R., Drewe J., Huber P., Herzog R., Müller B. TSH-Controlled L-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study). **J Clin Endocrinol Metab** 2001; 86: 4860-4866 IF 6.3
Editorials: - McDermott M.T. and Ridgway E.C. Subclinical Hypothyroidism Is Mild Thyroid Failure and Should be Treated. **J Clin Endocrinol Metab** 2001; 86: 4585-4590
- Chu J.W. and Crapo L.M. The Treatment of Subclinical Hypothyroidism Is Seldom Necessary. **J Clin Endocrinol Metab** 2001; 86: 4591-4599
Awards: - Best oral presentation Annual Meeting SGIM 2001 (cf. Abstract #48)
- Finalist Award of the Endocrine Society & Pharmacia Corporation
International Award for Excellence in Published Clinical Research 2002
16. Wagner K.E., Martinez J.M., Vath SD, Snider R.S., Nylen E.S., Becker K.L., Müller B., White J.C. Early Immunoneutralization of Calcitonin Precursors Markedly Attenuates the Adverse Response to Sepsis in Pigs. **Crit Care Med** 2002; 30: 2313-21 IF 6.5
25. Linscheid P., Seboek D., Nylen E.S., Langer I., Schlatter M., Keller U., Becker K.L., Müller B.: In Vitro and in Vivo Calcitonin I Gene Expression in Parenchymal Cells: A Novel Product of Human Adipose Tissue. **Endocrinology** 2003; 144: 5578-5584 IF 5.0
Award: Servier Award of the Swiss Society of Endocrinology and Diabetes (SSED/SGED) 2004
30. Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M., Huber P.R., Tamm M. and Müller B. Effect of Procalcitonin-Guided Therapy on Antibiotic Use and Outcome in Lower Respiratory Tract Infections: cluster-randomized, single-blinded trial. **THE LANCET** 2004; 363: 600-607, Epub Feb 10, 2004 ("Fast track" publication) IF 60.3
Talking points: Antibiotics: a breath of fresh air? **The Lancet** 2004; 363: 579
Journal Club: Al-Nakeeb S., Clermont G., Procalcitonin testing has the potential to reduce the unnecessary antibiotic use in patients with lower respiratory tract infections. **Crit Care** 2005; E5
(<http://ccforum.com/articles/browse.asp?sort=Journal%20club%20critique&date=2-2005>)
Correspondence: Christ-Crain M., Jaccard-Stolz D., Tamm M. and Müller B. Procalcitonin-guided antibiotic therapy in heart failure. **The Lancet** 2004; 363: 1555-6
Awards: - SGIM 2004 Lausanne: Highlight & Poster Award (1st Prize, cf Abstract #97)
- Stiftung Pfizer Forschungs-Preis 2005
- Wissenschaftlicher Förderpreis Viollier 2005
46. Widmer I., Puder J., Koenig C. Pargger H., Zerkowski H.R., Müller B. Cortisol Response in relation to the Severity of Stress and Illness: The "CORESSI"-Study **J Clin Endocrinol Metab** 2005; 90: 4579-86 IF 6.3
Editorial: Dickstein G: On the Term "Relative Adrenal Insufficiency"--or What Do We Really Measure with Adrenal Stimulation Tests? **J Clin Endocrinol Metab** 2005;90 4973-4974

62. Christ-Crain M., Stolz D., Bingisser R., Müller C., Miedinger D., Huber P.R., Zimmerli W., Harbarth S., Tamm M. and Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial **Am J Resp Crit Care Med** 2006; 174: 84-93 IF 11.1
Editorial: Wunderink R.G. A CAP on Antibiotic Duration. **Am J Resp Crit Care Med** 2006; 174: 3-5
Award: Prize of the Swiss Society of Internal Medicine (SGIM) 2007
69. Stolz D., Christ-Crain M., Bingisser R., Gencay M., Huber P.R., Müller C., Leuppi J., Müller B and Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. **Chest** 2007; 131: 9-19 IF 5.3
Editorial: Martinez F.J., Curtis J.L. Procalcitonin-Guided Antibiotic Therapy in COPD Exacerbations: Closer But Not Quite There. **Chest** 2007; 131: 1-2
Award: Forschungspreis der Schweizerischen Gesellschaft für Pneumologie (GlaxoSmithKline) 2006
78. Conen D., Melly L., Kaufmann C., Bilz S., Amman P., Schär B., Sticherling C., Müller B., Osswald S. Amiodarone-induced thyrotoxicosis: long-term follow-up and independent predictors of outcome. A retrospective cohort study. **J Am Coll Cardiol** 2007; 49: 2350-5 IF 14.2
Award: Mary & Ewald Betschmann Award for best thesis University Basel, 2007
99. Briel M., Schütz P, Müller B.*, Young J, Nusbaumer C., Périat P, Bucher H.C., Christ-Crain M.. Procalcitonin-guided antibiotic use versus standard approach for acute respiratory tract infections in primary care (*corresponding author)
Arch Int Med – JAMA Internal Medicine 2008;168: 2000-7 IF 11.5
Invited Commentary: Schwartz D.N. **Arch Int Med – JAMA Internal Medicine** 2008; 168: 2007-8
111. Schuetz P., Christ-Crain M., Thomann R., Falconnier C., Wolbers M., Widmer I., Neidert S., Fricker T., Blum C., Schild U., Regez K., Schoenenberger R., Henzen C., Breggenzer T., Hoess C., Krause M., Bucher H.C., Zimmerli W. and Mueller B., for the ProHOSP Study Group. Effect of Procalcitonin-based Guidelines Compared to Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The Randomized-Controlled ProHOSP Trial. **JAMA** 2009; 302: 1059 - 66 IF 47.7
Editorial: Yealy D.M., Fine M.J. Measurement of Serum Procalcitonin. A step closer to tailored care for Respiratory Infections. **JAMA** 2009; 302: 1115-6
@Letter: Schuetz P., Zimmerli W., Mueller B. Procalcitonin-Based Guidelines and Lower Respiratory Tract Infections – Reply. **JAMA**. 2010;303:419-420 doi:10.1001/jama.2010.54
121. Baehni C., Meier S., Spreiter P., Schild U., Regez K., Bossart R., Thomann R., Falconnier C., Christ-Crain M., De Geest S., Mueller B. and Schuetz P. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. **BMC Pulmonary Med** 2010, 10:12 <http://www.biomedcentral.com/1471-2466/10/12> IF 1.6
132. Gencay M.M.C., Stolz D., Christ-Crain M., Müller B., Roth M. and Tamm M. Single and multiple viral infections in lower respiratory tract infection. **Respiration** 2010; 80: 560-7 IF 2.3
Editorial: Hegele R.G. Viruses and Lower Respiratory Tract Infections: Does more mean worse? **Respiration** 2010; DOI: 10.1159/000320329
137. Guertler C., Wirz B., Christ-Crain M., Zimmerli, W., Müller B.*, Schuetz P. Inflammatory response on admission predicts long term mortality risk in community-acquired pneumonia. **Eur Resp J** 2011; 37: 1439–1446 IF 16.7
Editorial: Mortensen E.M. Potential causes of increased long-term mortality after pneumonia **Eur Respir J** 2011; 37: 1306–1307
138. Timper K., Grisouard J., Radimerski T., Dembinski K., Peterli R., Frey D.M., Haering A., Zulewski H., Keller U., Müller B. and Christ-Crain M. Glucose-dependent insulinotropic polypeptide (GIP) induces calcitonin gene related peptide (CGRP) and procalcitonin (Pro-CT) production in human adipocytes. **J Clin Endocrinol Metab** 2011; 96:E297-303. Epub 2010 Nov 24 IF 6.3
151. Albrich W.C., Dusemund F., Bucher B., Meyer S., Thomann R., Kühn F., Bassetti S., Sprenger M., Baechli E., Sigrist Th., Schwietert M., Amin D., Hausfater P., Carre E., Gaillat J., Schuetz P., Regez K., Bossart R., Schild U., Müller B. Effectiveness and safety of Procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter post-study survey (ProREAL). **Arch Int Med – JAMA Internal Medicine** 2012; 172: 715-22 IF 11.5
Editorial: Gilbert D. Serum Procalcitonin levels. It is all about confidence. **Arch Int Med – JAMA Internal Medicine** 2012; 172: 722-3
168. Schuetz P., Müller B., Christ-Crain M., Stolz, D., Tamm M., Bouadma L., Luyt C.E., Wolff M., Chastre J., Tubach F., Kristoffersen K.B., Burkhardt O., Welte T., Schroeder S., Nobre V., Wei L., Bhatnagar N., Bucher H.C., Briel M. Procalcitonin to initiate or withhold antibiotic therapy in acute respiratory tract infections – an individual patient data (IPD) analysis. **Cochrane DB Syst Rev** 2012; 9: 1 - 71 IF 5.9
 - Discussed in: **Ann Int Med** 2013; 158:JC5 Therapeutics
177. Albrich W.C., Rüegger K., Dusemund F., Schuetz P., Arici B., Litke A., Blum C., Bossart R., Regez K., Schild U., Guglielmetti M., Conca A., Schäfer P., Schubert M., de Geest S., Reutlinger B., Irani S., Bürgi U., Huber A.,

Mueller B. Biomarker-enhanced triage in respiratory infections – a proof-of-concept feasibility trial.

Eur Respir J 2013; 42: 1064-75 DOI: 10.1183/09031936.00113612

IF 16.7

Editorials:

Krüger S., Frechen D. Another brick in the wall – adrenomedullin and prognosis in community-acquired pneumonia. **Eur Respir J** 2012; 39: 1060-61

Kolditz M., Ewig S., Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. **Eur Respir J** 2013; 41: 974-984

Jensen J.U. Biomarker-guided clinical decisions: for patients, health-economists or neither

Eur Respir J 2013; 42: 895 - 7

185. Leuppi J.D.*, Schütz P.*, Bingisser R., Bodmer M., Briel M., Drescher T., Duerring U. Henzen C., Leibbrandt Y., Maier S., Miedinger D., **Mueller B.**, Scherr A., Schindler C., Stoeckli R., Viatte S., von Garnier C., Tamm M., Rutishauser J. Short-term versus standard glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: “REDUCE”, a randomized controlled trial.

JAMA 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023

IF 47.7

Editorial:

Sin D.C., Hye Y.P. Steroids for Treatment of COPD Exacerbations – Less is clearly more **JAMA** 2013;

203. Thommen D., Weissenberger N., Schuetz P., **Mueller B.**, Reemts C., Holler T., Schifferli J.A., Gerber M., Hug B.L. Head-to-head Comparison of Length of Stay and Quality of Care in Switzerland before and after DRG-Implementation in 2012: An Observational Study in Two Tertiary University Centers.

Swiss Med Wkly 2014; 144:w13972

IF 1.9

211. Schuetz P., Balk R., Briel M., Kutz A., Christ-Crain M., Stolz D., Bouadma L., Wolff M., Kristoffersen K. B., Wei L., Burkhardt O., Welte T., Schroeder S. Nobre V., Tamm M., Bhatnagar N., Bucher H.C., Luyt C.-E., Chastre J., Tubach F., **Mueller B.**, Lacey M.J., Ohsfeldt R.L., Scheibling C. M., Schneider J.E. Economic Evaluation of Procalcitonin-Guide Antibiotic Therapy in Acute Respiratory Infections: A U.S. Health System Perspective.

Clinical Chemistry and Laboratory Medicine (CCLM) 2015; DOI 10.1515/cclm-2014-1015

IF 3.0

212. Blum C.A., Nigro N., Briel M., Schuetz P., Ullmer E., Suter-Widmer I., Winzeler B., Bingisser R., Elsaesser H., Drozdov D., Birsén A., Urwyler S.A., Refardt J., Tarr P., Wirz S., Thomann R., Baumgartner C., Duplain H., Burki D., Zimmerli W., Rodondi N., **Mueller B.**, Christ-Crain M. Adjunct prednisone therapy for patients with community-acquired pneumonia – a randomized, double-blind, placebo-controlled multicenter trial.

The Lancet 2015; Fast track publication [http://dx.doi.org/10.1016/S0140-6736\(14\)62447-8](http://dx.doi.org/10.1016/S0140-6736(14)62447-8)

IF 60.3

Award:

- Best Publication of the Year. Swiss Society of Internal Medicine (SGIM) 2015

Authors reply:

Blum C.A., Briel M., Schuetz P., Mueller B., Christ-Crain M. Corticosteroid therapy for pneumonia. **Lancet** 2015; 386: 956

218. Karakoumis J., Nickel C.H., Kirsch M., Rohacek M., Geigy N., **Mueller B.**, Ackermann S., Bingisser R. Emergency Presentations with nonspecific complaints – the burden of morbidity and the spectrum of underlying disease **Medicine** 2015; 94: e840 DOI: 10.1097/MD.0000000000000840

IF 5.4

230. Conca A., Bossart R., Regez K, Schild U, Wallimann G., Schweingruber R, Hantikainen V., Tobias P., Albrich W. C., Rüegger K., Dusemund F., Bürgi U., Sigrist T., Mariacher-Gehler S., Huber A., Schütz P., Müller, B. and Reutlinger B. Optimized Patient Transfer through Innovative Multidisciplinary Assessment: Project Description of Phase I [Translated from the original article in German published in *Pflegewissenschaft* 2012; 5:291-8]

J Nurs Care 2015 (11):584-597. <http://dx.doi.org/10.4172/2167-1168.1000316>

240. Kutz A., Florin J., Hausfater P., Amin D., Amin A., Haubitz S., Conca A., Reutlinger B., Cavanaggio P., Sauvin G., Bernard M., Huber A., **Mueller B.**, and Schuetz P. for the TRIAGE study group. Predictors for delayed emergency department care in medical patients with acute infections – an international prospective observational study. **PLoS ONE** 2016; 11: e0155363 DOI 10.1371/journal.pone.0155363

IF 4.1

257. Straubhaar K., Schuetz P., Blum C.A., Nigro N., Briel M., Christ-Crain M., **Mueller B.** Influence of hospital characteristics on quality of care in patients with community-acquired pneumonia.

Swiss Med Wkly 2016;146:w14337; <https://doi.org/10.4414/smw.2016.14337>

IF 2.0

265. Schuetz P., Meier M.A., Bally M.R., Gomes F., **Mueller B.** Industry sponsorship and outcomes of nutrition studies: Is there an association when looking at the trial level ?

J Clinical Nutrition 2017; 36: 616-8

IF 5.5

275. Burgemeister S., Kutz A., Conca A., Holler T., Haubitz S., Huber A., Buergi U., **Mueller B.**, Schuetz P. Comparative quality measures of emergency care: an outcome cockpit proposal to survey clinical processes in real life. **Open Access Emergency Medicine** 2017; 9: 1-10

279. Conca A., Ebrahim D., Noack S., Gabele A., Weber H., Prins M., Keller A., Hari M., Engel A., Regez K., Schild U., Schuetz P., **Müller B.**, Haubitz S., Kutz A., Huber A., Faessler L., Schäfer-Keller P. Screening by social workers in medical patients with risk of post-acute care needs: a stepped wedge cluster randomized trial. (Evaluation eines Screenings durch Sozialarbeiter bei medizinischen Patienten mit einem Risiko für post-akuten Nachsorgebedarf: eine stepped wedge clusterrandomisierte Studie).

Int J Health Prof 2018; 5: 18-24 <https://doi.org/10.2478/ijhp-2018-0003>

286. Fenske W., Refardt J., Chifu I., Schnyder I., Winzeler B., Drummond J., Ribeiro-Oliveira A., Drescher T., Bilz S., Vogt D.R., Malzahn U., Kroiss M., Christ E., Henzen C., Fischli S., Tönjes A., Mueller B., Schopohl J., Flitsch J., Brabant G., Fasnacht M., Christ-Crain M. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. **New Engl J Med** 2018; 379(5):428-439. <https://doi.org/10.1056/NEJMoa1803760> IF 79.3
Editorial: Rosen C.J. and Ingelfinger J.R. A Reliable Diagnostic Test for Hypotonic Polyuria: New Engl J. Med 2018; 379: 483-4
300. Schuetz P., Fehr R., Baechli V., Geiser M., Deiss M., Gomes F., Kutz A., Tribolet P., Bregenzer T., Braun N., Hoess C., Pavlicek V., Schmid S., Bilz S., Sigrist S., Brändle M., Benz C., Henzen C., Mattmann S., Thomann R., Brand C., Rutishauser J., Aujesky D., Rodondi N., Donze J., Stanga Z., Mueller B. Individualized nutritional support in medical inpatients at nutritional risk: a randomized clinical trial. **Lancet** 2019 [http://dx.doi.org/10.1016/S0140-6736\(18\)32776-4](http://dx.doi.org/10.1016/S0140-6736(18)32776-4) IF 60.3
Editorial: Changing outcome with a little EFFORT.
Lancet 2019 [http://dx.doi.org/10.1016/S0140-6736\(18\)32856-3](http://dx.doi.org/10.1016/S0140-6736(18)32856-3)
Award: Prize of the Swiss Society of General Internal Medicine (SGAIM) 2019
Theodor Naegeli-Preis 2022
301. Kutz A., Gut L., Ebrahimi F., Wagner U., Mueller B., Schuetz P. Association of the Swiss Nation-wide Implementation of Diagnosis Related Groups Reimbursement with Length of Stay, Mortality, and Readmission Rates in Hospitalized Medical Patients. **JAMA Network Open** 2019 ;2(2):e188332. doi:10.1001/jamanetworkopen.2018.8332 IF
317. Kozhuharov N., Goudev A., Flores D., Maeder M.T., Walter J., Shrestha S., Gualandro D.M., Oliveira M.T., Sabti Z., Mueller B., Noveanu M., Socrates T., Ziller R., Bayés-Genis A., Sionis A., Simon P., Michou E., Gujer S., Gori T., Wenzuel P., Pfister O., Conen D., Kapos I., Kobza R., Rickli H., Breidhardt T., Muenzel T., Erne P., Mueller C., for the GALACTIC Investigators. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality or Heart Failure Rehospitalization among Patients with Acute Heart Failure. **JAMA** 2019;322(23):2292-2302. <https://doi:10.1001/jama.2019.18598> IF 47.7
Award: Pfizer Research Prize 2021
325. Merker M., Felder M., Gueissaz L., Bolliger R., Tribolet P., Braun N., Hoess C., Pavlicek V., Bilz S., Sigrist S., Braendle M., Henzen C., Thomann R., Rutishauser J., Aujesky D., Rodondi N., Donzé J., Stanga Z., Mueller B., Schuetz P. Association of Baseline Inflammation with Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition – Secondary analysis of a randomized multicenter trial. **JAMA Network Open** 2020;3(3):e200663 <https://doi:10.1001/jamanetworkopen.2020.0663> IF 5.0
Award: Prize of the Swiss Society of General Internal Medicine 2021 (CHF 10'000.-)
326. Urwyler S.A., Ebrahimi F., Burkard T., Schuetz P., Poglitsch M., Mueller B., Donath M.Y., Christ-Crain M. IL (Interleukin) 1-receptor antagonist increases angiotensin-(1-7) and decreases blood pressure in obese individuals. **Hypertension** 2020; <https://doi:10.1161/HYPERTENSIONAHA.119.13982> IF 7.7
Award: Viollier Prize 2021
329. Bernet S., Gut L., Baechli C., Koch D., Wagner U., Mueller B., Schuetz P., Kutz A. Association of weekend admission and clinical outcomes in hospitalised adult patients with sepsis. **Medicine** 2020; 99: 26: 1-6 <http://dx.doi.org/10.1097/MD.00000000000020842> IF 2.1
330. Koch D., Kutz A., Haubitz S., Baechli C., Gregoriano C., Conca A., Volken T., Schuetz P., Mueller B. Association of functional status and hospital-acquired functional decline with 30-day outcomes in medical inpatients: A prospective cohort study. **Applied Nursing Research** 2020; 54: 151274 <https://doi.org/10.1016/j.apnr.2020.151274> IF 2.2
334. Gregoriano C., Koch D., Haubitz S., Conen A., Fux C.A., Mueller B., Bernasconi L., Hammerer A., Oberle M., Burgemeister S., Reiter R., Kutz A., Schuetz P. Characteristics, predictors and outcomes among 99 patients hospitalized with COVID-19 in a tertiary care center in Switzerland: an observational analysis. **Swiss Med Wkly** 2020;150:w20316 <https://DOI.org/10.4414/smw.2020.20316> IF 1.8
338. Koch D., Kutz A., Conca A., Wenke J., Schuetz P., Mueller B. The relevance, feasibility and benchmarking of nursing quality indicators: A Delphi study. **J Adv Nurs** 2020; 00: 1-12 <https://doi:10.1111/jan.14560> IF 2.5
352. Mueller M., Huembelin M., Baechli C., Wagner U., Schuetz P., Mueller B., Kutz A. Association of in-hospital multimorbidity with patient-oriented healthcare outcomes in Swiss medical inpatients. **Swiss Med Wkly** 2021, 151:w20405. IF 2.2
360. Becker C., Gamp M., Schuetz P., Beck K., Vincent A., Hochstrasse S., Metzger K., Widmer M., Thommen E., Mueller B., Fux C.A., Leuppi J., Schaefer R., Langewitz W., Trendelenburg M., Breidhart T., Eckstein J., Osthoff M., Bassetti S., Hunziker S. Effect of Bedside Patient Case Presentation on Patients' Medical Knowledge. **Ann Int Med** 2021; <https://doi.org/10.7326/M21-0909>174(9):1282-1292. IF 3.2
Editorial: LaCombe M.A. Bringing Teaching back to the Bedside.
Ann Int Med 2021 <https://doi.org/10.7326/M21-2447>
Award: Best Presentation Ann. Meeting Swiss Society of General Internal Medicine SGAIM May 2021
385. Koch D., Kutz A., Volken T., Gregoriano C., Conca A., Kleinknecht-Dolf M., Schuetz P., Mueller B. Derivation and validation of a prediction model to establish nursing-sensitive quality benchmarks in medical inpatients: a

secondary data analysis of a prospective cohort study.

Swiss Med Wkly 2022;152:w30152 <https://doi.org/10.4414/SMW.2022.w30152>

IF 2.1

400. Kutz A., Koch D., Haubitz S., Conca A., Baechli C., Regez K., Gergoriano C., Ebrahimi F., Bassetti S., Eckstein J., Beer J., Egloff M., Kaeppli A., Ehmann T., Hoess C., Schaad H., Wharam J.F., Lieberherr A., Wagner U., de Geest S., Schuetz P., Mueller B. Association of Interprofessional Discharge Planning Using an Electronic Health Record Tool With Hospital Length of Stay Among Patients with Multimorbidity A Nonrandomized Controlled Trial. **JAMA Network Open**. 2022;5(9):e2233667. <https://doi.org/10.1001/jamanetworkopen.2022.33667> IF 13.3
401. Struja T., Suter F., Rohrmann S., Koch D., Mueller B., Schuetz P., Kutz A. Comparison of Cardiovascular Procedure Rates in Patients With Supplementary vs Basic Insurance in Switzerland. **JAMA Network Open**. 2023;6(1):e2251965. <https://doi.org/10.1001/jamanetworkopen.2022.51965>
405. Faessler L., Kofler S., Wenke-Zobler J., Bunner C., Schäfer-Keller P., de Geest S., Schubert M., Regez K., Schuetz P., Mueller B., Conna A. Nursing Open 2023; 00: 1-12 The use of nurse-led care intervention to improve self-care abilities subsequently decreasing readmission in multimorbid hospitalized patients: A quasi-experimental study in a real-world setting. **Nursing Open** 2023; 00: 1-12 <https://doi.org/10.1002/nop2.1637>
406. Gregoriano C., Rafaisz K., Schuetz P., Mueller B., Fux C.A. Conen A., Kutz A. Burden of disease in patients hospitalised with COVID-19 during the first and second pandemic wave in Switzerland: a nationwide cohort study. **Swiss Med Wkly** Swiss Med Wkly. 2023;153:40068 <https://doi.org/10.57187/smw.2023.40068>
409. Siegwart J., Spennato U., Lerjen N., Mueller B., Schuetz P., Koch D., Struja T. Prediction of in-hospital falls by NRS, PACD Score and FallRS. A retrospective cohort study. **Geriatrics** 2023, 8, 60 <https://doi.org/10.3390/geriatrics8030060> <https://doi.org/10.3390/geriatrics8030060>

B. Uebersichtsarbeiten in referierten Zeitschriften (Reviews, peer-reviewed)

48. Schuetz P., Aujesky D., Mueller C., Mueller B. Biomarker-guided Personalized Emergency Medicine for All – Hope for another Hype ?. **Swiss Med Wkly** 2015 ;145:w14079 IF 1.9
58. Kutz A., Ebrahimi F., Struja T., Greenwald J.L., Schuetz P., Mueller B. Innovative transition interventions to better align health care need in hospitalized medical patients **Swiss Med Wkly** 2017; 147:w14515 <https://doi.org/10.4414/smw.2017.14515> IF

C. Monographien, Korrespondenzen, Fallberichte & Editorials

1. Müller B., Bürgi U., König M.-P. In Presseorganen angepriesene Schlankheitskuren. **Inaugural Dissertation (Thesis)**. Div. of Endocrinology, Dept. of Medicine, Inselspital, University of Bern, Switzerland. 1990; 1-77
2. Müller B. The Thyroid as a Prototype of a Hormokine secreting Organ. **Habilitationsschrift (Postdoctoral Thesis)**. Department of Internal Medicine, University of Basel, Switzerland 2002
19. Müller B., Christ-Crain M., Schütz P. Meta-analysis of observational studies lacking a gold-standard – an unresolved dilemma. **Lancet Inf Dis** 2007; 7: 498-9 IF 25.1
44. Mueller B., Bürgi U. Notfall an einem grossen Kantonsspital und dessen Reorganisation – Urgences dans un grand hospital cantonal et leur reorganization – **Schweiz Med Forum Forum Med Suisse** 2014; 14: 477
47. Giessen H., Nebiker C.A., Bruehlmeier M., Spreitzer S., Mueller B., Schuetz P. Do you want to participate in a clinical study as a healthy control? - Risk or benefit?. **World Journal of Clinical Cases**, 2017; 5 (12): 437-439 IF 1.9
50. Kutz A., Schuetz P., Mueller B. Integrierte Patientenbetreuung – Innovationsprojekt vor dem Start. **Competence** 2017; 5: 28-29
51. Schuetz P., Mueller B. Procalcitonin-guided antibiotic stewardship from newborns to centenarians. **Lancet** 2017 [http://dx.doi.org/10.1016/S0140-6736\(17\)31628-8](http://dx.doi.org/10.1016/S0140-6736(17)31628-8) IF 60.3
54. Koch D., Conca A., Regez K., Schuetz P., Kutz A., Mueller B. Integrierte und interprofessionelle Verbesserung der Patientenbetreuung – das InHospITOOL Projekt. **Pflegewissenschaft** 2018; 20: 7-12
56. Aujesky D., Bassetti S., Battegay E., Cornuz J., Hess C., Leuppi D., Mueller B., Reny J.-L., Rodondi N., Vollenweider P., Waeber G., Gaspoz J.-M. Aktionsplan für die Universitäre Allgemeine Innere Medizin. **Schweizerische Aerztezeitung** 2018;99(38):1262–1265
57. Kutz A., Schuetz P., Mueller B. SwissDRG und nutzerorientierte Kennzahlen – Zeit, Bilanz zu ziehen. **Schweizerische Aerztezeitung** 2019;100(14):523–4

IV. LEHRE

A. Verzeichnis der universitären Lehrveranstaltungen (Auswahl)

- Vorlesungen für Medizinstudenten im Themenblock 3. u 4. Jahreskurs (1999 -)
Award: „Teacher of the Year“ medizinische Fakultät Uni Basel

B. Eingeladene Vorträge (national und international)

N >300

V. NACHWUCHSFÖRDERUNGEN & “MENTORSHIPS”

A. Betreute Habilitationen Medizinische Fakultät (Postdoctoral Theses)	N = 6
B. Betreute Dissertationen Medizinische Fakultät (MD Theses)	N = 60
C. Betreute experimentelle Dissertationen Phil. Nat. Fakultät (PhD Thesis)	N = 2
D. Betreute Masterarbeiten der Medizinischen Fakultät der Universität Basel	N = >60
E. Förderungen von Pflegefachkräften und Laborantinnen	N = 8
F. Drittmittel finanzierte Schwangerschafts- und Mutterschaftsurlaube	N = 5

VI. WISSENSCHAFTLICHE AUSZEICHNUNGEN & EINGEWORBENE DRITTMITTEL

Stand 05. September 2023

Total eingeworbene Drittmittel: CHF 21'789'332.-

A. Auszeichnungen & Preise	Total CHF 500'090.-
B. Drittmittel als “Principal Investigator” & “Co-Principal Investigator”	Total CHF 15'712'271.-
C. Drittmittel als Co-Investigator & Mentor	Total CHF 5'576'971.-
F. Potentielle Interessenskonflikte	

I have been wined, dined, supported, transported, consulted, and paid to speak by countless pharmaceutical firms for more than 30 years, beginning with research fellowships, educational grants and interest-free loans that allowed me to finish my pre- and post-graduate medical education.

Several of my investigator initiated, clinical and experimental studies have been supported in part (but never in whole) by pharmaceutical firms, who have never had the power of veto over any data, analyses, reports, presentations, or publications of the results.

I received several awards which were directly or indirectly sponsored by pharmaceutical companies.

VII. FORSCHUNGSSCHWERPUNKTE UND LAUFENDE PROJEKTE

I. Versorgungsforschung („Comprehensive Effectiveness Research“)

Ziel: Outcome-orientierte Versorgungsforschung bei akuthospitalisierten, polymorbiden medizinischen Patienten , unter anderem, mit Hilfe von Biomarkern. Dies mit dem Ziel einer risikostratifizierteren Diagnostik, Therapie und Allokation limitierter Spitalressourcen unter Anwendung von fach-, berufs-, und institutions-übergreifenden Ansätzen.

Methodik: Randomisierte, multizenter Interventionsstudien, Observationsstudien, Meta-Analysen

VIII. REFERENZEN

Aus Verwaltungsratsmandaten

- * Dr. Thomas Heiniger
Verwaltungsratspräsident
Psychiatrie Baselland (PBL)
th@thomasheiniger.ch
Mobile 079 224 3292

- * Dr. med. Wolfgang Czerwenka
Verwaltungsrat, Verwaltungsratspräsident (bis Juni 2023)
ARGOMED AG
wolfgang.czerwenka@hin.ch
Mobile 079 241 7369

Kantonsspital Aarau AG

- * Peter Suter
Ehemaliger Verwaltungsratspräsident (bis Juni 2023)
petersuter@highspeed.ch
Tel. 56 437 00 10; Mobile 079 407 7777

- * Hr. Anton Schmid
Chief Executive Officer (CEO)
anton.schmid@ksa.ch
Mobile 079 792 94 58

Universitätsspital Basel

- * Prof. Jürg Schifferli
Verwaltungsrat Universitäre Altersmedizin Felix-Platter Spital (UAFP, Felix-Platter-Spital (FPS))
j.schifferli@unibas.ch
Mobile 079 771 8515

- * Prof. André Perruchoud
Ehemaliger Verwaltungsrat Universitätsspital Basel (USB)
Andre.Perruchoud@usb.ch
Mobile 079 322 4451



5. September 2023